1 / 27

EORTC STBSG

EORTC STBSG. Ongoing clinical trials Venice, November 4th. A RANDOMIZED STUDY COMPARING NEOADJUVANT CHEMOTHERAPY ETOPOSIDE + IFOSFAMIDE + ADRIAMYCIN (EIA) COMBINED WITH REGIONAL HYPERTHERMIA (RHT) VS. NEOADJUVANT CHEMOTHERAPY ALONE

afric
Download Presentation

EORTC STBSG

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EORTC STBSG Ongoing clinical trials Venice, November 4th

  2. A RANDOMIZEDSTUDY COMPARINGNEOADJUVANT CHEMOTHERAPY ETOPOSIDE + IFOSFAMIDE + ADRIAMYCIN (EIA) COMBINED WITH REGIONAL HYPERTHERMIA (RHT) VS. NEOADJUVANT CHEMOTHERAPY ALONE IN THE TREATMENT OF HIGH-RISK SOFT TISSUE SARCOMAS IN ADULTS AN INTERGROUP STUDY WITH THE EUROPEAN SOCIETY FOR HYPERTHERMIC ONCOLOGY

  3. PROTOCOL 62981: Randomized Phase III study to evaluate the role of high dose chemotherapy intensification in the treatment of intermediate prognosis Ewing’s sarcoma and Primitive Neuroectodermal Tumour (PNET) Study Coordinator: I. Judson, London • VIDE: • Vincristine • Ifosfamide • Doxorubicin • Etoposide • Eligibility: • Ewing/PNET • < 50 years • No previous chemo • VAI: • Vincristine • Actinomycin • Ifosfamide • Stratification: • Age • Local trt of primary • VAC: • Vincristine • Actinomycin D • Cyclophosphamide • Bu-mel: • Busulfan • Melphalan

  4. PROTOCOL 62991-22998: Phase II study of moderate dose radiotherapy for inoperable aggressive fibromatosis Study coordinator: Ronald KEUS, Arnhem • Eligibility: • Histologically confirmed aggressive fibromatosis • Measurable disease (RECIST) • No current endocrine or chemotherapy, no prior or concurrent limb perf with TNF • >15 years

  5. PROTOCOL 62991-22998: ACCRUAL GRAPH

  6. PROTOCOL 62012: Randomized trial of single agent doxorubicin versus doxorubicin plus ifosfamide Study Coordinator: I. Judson, London • Eligibility: • High grade STS (2-3) • Age 16-60 • No previous chemo for adv/met dis • WHO PS < 2 • Stratification: • Age (<50 vs ≥50) • PS (0 vs 1) • Liver mets (0 vs +) • Histological grade (2 vs 3)

  7. Study 62012: accrual on 30/10 204 patients

  8. PROTOCOL 62022: Phase II study of Iressa (ZD1839) in locally advanced and/or metastatic synovial sarcoma Study Coordinator: J-Y Blay, Lyon ZD1839 500 mg/day orally once a day for at least 52 weeks • Eligibility: • Advanced/metastatic synovial sarcoma expressing HER1 Ag (DAKO or another mAb) • Frozen tissue available for genetic confirmation of the diagnosis and molecular anal. • One previous line of chemotherapy containing doxorubicin and/or ifosfamide

  9. PROTOCOL 62024: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery Collaborating Groups: ISG, FSG, EORTC STBSG, GEIS, AGITG Study Coordinators: P. CASALI, Milan (ISG) and J-Y BLAY, Lyon (EORTC STBSG) • Eligibility: • GIST with positive immunostaining for KIT • Risk of relapse documented on surgical specimen • No evidence of residual macroscopic disease after surg • No distant metastases • WHO PS 0-2, age >17 • No prior radiation therapy /chemotherapy After complete surgery • Stratification: • Risk category • Tumour site • Resection level • Main endpoint: • Overall survival • Secondary endpoints: • Relapse-free survival • Relapse-free interval • toxicity

  10. PROTOCOL 62024: Accrual by Group

  11. PROTOCOL 62024: Stratification factors

  12. PROTOCOL 62027: Phase II study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcoma expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF-beta fusion protein i.e DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF). Study Coordinator: A.T. Van Oosterom, Leuven GLIVEC 400 mg bid for at least 14 weeks • Eligibility: • Histologically proven locally advanced or metastatic DFSP or GCF • Progressive disease documented in the last 3 months • Disease not amenable to surgery, radiation or combined modality treatment with curative intent • Frozen tumor or paraffin embedded tissue available for immunohistochemical, molecular analysis and central path. review • No prior chemotherapy or no more than 1 line combination chemo with Ifosfamide and Doxorubicin or 2 lines of single agent therapy or relapsing within 6 months after end of adjuvant chemo. • WHO PS 0-2, age 18 years or more

  13. 62027 Accrual

  14. Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma EORTC study 62043

  15. Accrual graph (cut-off 11 Oct ’06)

  16. Phase II study of E7389 administered as an IV infusion day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcoma EORTC study 62052

  17. Trial 62052 Study Coordinator :Dr. Patrick Schoeffski (Leuven, Belgium) Date of PRC protocol approval:July 17, 2006 Version and date of last amendment: first amendment (non-substantial) protocol version 1.1, August 8, 2006 Treatment scheme : Intravenous bolus of E7389 (1.4 mg/m²) on days 1 and 8 every 21 days

  18. Sample size • The trial will be independently conducted in 4 groups of patients (strata) : • Leiomyosarcoma • Liposarcoma • Synovial sarcoma • Other types of eligible STS • STEP 1: 17 eligible patients per stratum • STEP 2: • if > 3 successes in step 1 : continue up to 37 eligible patients per stratum

  19. Randomized Phase II study of brostacillin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma EORTC study 62061 Study Coordinator :Dr. Hans Gelderblom

  20. Trial 62061 Date of PRC protocol approval :June 29, 2006 Treatment scheme : max 6 cycles treatment ARM A : Brostallicin 10 min. IV infusion (10 mg/m²) on day 1 of a q3w cycle (12.5 mg/m² from second cycle in case of good tolerance) ARM B :Doxorubicin IV bolus (75 mg/m²) on day 1 of a q3w cycle Sample Size : 72 (brostacillin) + 36 (doxorubicin)

  21. Eligibility Main eligibility criteria : • Histological or cytological confirmed high or intermediate grade malignant soft tissue sarcoma • Objective documentation of disease progression within the last 6 months. Relapsed or refractory disease incurable by surgery or radiotherapy. Presence of measurable disease (RECIST). • No prior chemotherapy regimen for advanced or metastatic disease; (neo)adjuvant therapy is allowed. • At least 60 years of age, or patients at least 18 years of age non suitable for intensive chemotherapy combination treatments • WHO performance status 0 or 1 • Adequate bone marrow, hepatic and renal function

  22. End-Points Primary: • 6 months progression-free survival (assessed at 26 weeks) Secondary: • Overall progression-free survival • Overall survival • Objective tumor response (RECIST) • Duration of response

  23. Participating countries UK (6) The Netherlands (5) CA & EC approval Germany (7) Belgium (3) CA & EC approval Poland (1) France (3) Slovakia (1) EC approval 26 sites in 7 countries

More Related